Methotrexat-Therapie bei schwerer chronischer okulärer Graft versus Host Disease (GvHD)

Précis

Zur Behandlung der chronisch okulären GvHD kann eine Kombinationstherapie mit Methotrexat sinnvoll sein, insbesondere bei sonst therapierefraktären Patienten.

• Literatur

• 1 Wolff D, Bertz H, Greinix H et al. The treatment of chronic graft-versus-host disease: consensus recommendations of experts from Germany, Austria, and Switzerland. Dtsch Arztebl Int 2011; 108: 732-740
• 2 Dietrich-Ntoukas T, Cursiefen C, Westekemper H et al. Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss consensus conference on clinical practice in chronic GVHD. Cornea 2012; 31: 299-310
• 3 Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735
• 4 Ruutu T, Niederwieser D, Gratwohl A et al. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997; 19: 759-764
• 5 Messmer EM, Foster CS. Destructive corneal and scleral disease associated with rheumatoid arthritis. Medical and surgical management. Cornea 1995; 14: 408-417
• 6 Huang XJ, Jiang Q, Chen H et al. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2005; 36: 343-348